Literature DB >> 12102595

Kinetics and hydrolysis mechanism of polymeric prodrugs containing ibuprofen, ketoprofen, and naproxen as pendent agents.

L F Wang1, H N Chiang, P C Wu.   

Abstract

Polymeric prodrugs were prepared using methacrylic acid (MA) copolymerization with 2-hydroxyethyl methacrylate (HEMA), covalently linked with ibuprofen (HI), ketoprofen (HK), or naproxen (HN). It was previously shown that the acceptable composition of drug-linked monomer in polymeric prodrugs to prevent gastric mucosa irritation and maintain water solubility was in the range of 20-40 mol%. To investigate the applicability of these polymeric prodrugs, hydrolysis rates of HK-25, HN-29, and HI-30 (the number indicates the mole percent of the drug-linked monomers in the polymeric prodrugs), were studied in vitro with or without esterase. The polymeric prodrugs released a major fraction of the parent drugs and a fraction of the hydroxyethyl ester drug derivatives (drug-EtOH). The calculated hydrolysis rate constants and results correlated to the drug structural solubility and steric hindrance are discussed. The anti-inflammatory properties of these polymeric prodrugs were evaluated using carrageenan-induced edema test. The results indicate that HK-25 and HN-29 display greater potency to inhibit acute inflammatory processes than the free drugs over long periods. HI-30, however, retains a potency comparable to that of free ibuprofen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12102595     DOI: 10.1163/156856202320176538

Source DB:  PubMed          Journal:  J Biomater Sci Polym Ed        ISSN: 0920-5063            Impact factor:   3.517


  2 in total

1.  Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT.

Authors:  Xiaowan Zheng; James E Polli
Journal:  Int J Pharm       Date:  2010-07-01       Impact factor: 5.875

2.  A novel NSAID derivative, phospho-ibuprofen, prevents AOM-induced colon cancer in rats.

Authors:  Nengtai Ouyang; Ping Ji; Jennie L Williams
Journal:  Int J Oncol       Date:  2012-12-28       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.